Patent FR2344852B1 successfully refreshed from Google Patents.
US4569840A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Thymidine kinase-negative temperature resistant bovine herpesvirus-1 mutant as a vaccine against infectious bovine rhinotracheitis
Assignee: Novagene Ltd
•
Filing: 1983-07-21
•
Granted: 1986-02-11
•
Expires: 2003-07-21
Abstract
Abstract Described are thymidine kinase negative temperature resistant mutants of bovine herpesvirus effective in inducing resistance to infectious bovine rhinotracheitis, methods for their production, methods for maintaining them in viable form, and methods for administering them to animals in immunologically effective doses to induce resistance to infectious bovine rhinotracheitis.
Inventors
- 👤 Saul Kit
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 09:44
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; A61K39/265; A61K2039/51; A61K2039/525; A61K2039/5254; A61K2039/55; A61K2039/552; C; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16711; C12N2710/16734; Y; Y10; Y10S; Y10S424/00; Y10S424/813; Y10S424/815; Y10S424/822
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
18 words
A temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation.
Claim 2
Dependent Claim
18 words
A temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation.
Claim 3
Dependent Claim
20 words
The temperature-resistant bovine herpesvirus-1 as claimed in claim 1, wherein said virus has the identifying characteristics of ATCC No. VR-2066.
Claim 4
Dependent Claim
107 words
A temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation produced by a process comprising: (A) propagating thymidine kinase-positive bovine herpesvirus-1 in thymidine kinase-positive cells at about 34.5° C. in the presence of a mutagen and selecting for thymidine kniase-negative bovine herpesvirus-1; (B) plaque-purifiying the resulting thymidine kinase-negative bovine herpesvirus-1 so as to obtain bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase; and (C) propragating the resulting plaque-purified thymidine kinase-negative bovine herpesvirus-1 mutants in thymidine kinase-positive cells at about 39.1° C. and selecting for temperature-resistant bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase.
Claim 5
Dependent Claim
107 words
A temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation produced by a process comprising: (A) propagating thymidine kinase-positive bovine herpesvirus-1 in thymidine kinase-positive cells at about 34.5° C. in the presence of a mutagen and selecting for thymidine kniase-negative bovine herpesvirus-1; (B) plaque-purifiying the resulting thymidine kinase-negative bovine herpesvirus-1 so as to obtain bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase; and (C) propragating the resulting plaque-purified thymidine kinase-negative bovine herpesvirus-1 mutants in thymidine kinase-positive cells at about 39.1° C. and selecting for temperature-resistant bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase.
Claim 6
Dependent Claim
14 words
The temperature-resistant bovine herpesvirus-1 as claimed in claim 3, wherein said mutagen is 5-bromodeoxyuridine.
Claim 7
Dependent Claim
41 words
A modified-live virus vaccine for infectious bovine rhinotracheitis comprising: (A) a pharmaceutically effective amount of a temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation; and (B) a pharmaceutically acceptable carrier or diluent.
Claim 8
Dependent Claim
41 words
A modified-live virus vaccine for infectious bovine rhinotracheitis comprising: (A) a pharmaceutically effective amount of a temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation; and (B) a pharmaceutically acceptable carrier or diluent.
Claim 9
Dependent Claim
20 words
The modified-live virus vaccine as claimed in claim 5, wherein said virus has the identifying characteristics of ATCC No. VR-2066.
Claim 10
Dependent Claim
22 words
The modified-live virus vaccine as claimed in claim 5, wherein said pharmaceutical effective amount is about 10 6 to 10 8 PFU.
Claim 11
Dependent Claim
129 words
A modified-live virus vaccine for infectious bovine rhinotracheitis comprising: (A) a pharmaceutically effective amount of a temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation prepared by the process comprising: (1) propagating thymidine kinase-positive bovine herpesvirus-1 in thymidine kinase-positive cells at about 34.5° C. in the presence of a mutagen and selecting for thymidine kinase-negative bovine herpesvirus-1; (2) plaque-purifying the resulting thymidine kinase-negative bovine herpesvirus-1 so as to obtain bovine herpesvirus-1 mutants which fails to produce any functional thymidine kinase; and (3) propagating the resulting plaque-purified thymidine kinase-negative bovine herpesvirus-1 mutants in thymidine kinase-positive cells at about 39.1° C. and selecting for temperature-resistant bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase. (B) a pharmaceutically acceptable carrier or diluent.
Claim 12
Dependent Claim
129 words
A modified-live virus vaccine for infectious bovine rhinotracheitis comprising: (A) a pharmaceutically effective amount of a temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation prepared by the process comprising: (1) propagating thymidine kinase-positive bovine herpesvirus-1 in thymidine kinase-positive cells at about 34.5° C. in the presence of a mutagen and selecting for thymidine kinase-negative bovine herpesvirus-1; (2) plaque-purifying the resulting thymidine kinase-negative bovine herpesvirus-1 so as to obtain bovine herpesvirus-1 mutants which fails to produce any functional thymidine kinase; and (3) propagating the resulting plaque-purified thymidine kinase-negative bovine herpesvirus-1 mutants in thymidine kinase-positive cells at about 39.1° C. and selecting for temperature-resistant bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase. (B) a pharmaceutically acceptable carrier or diluent.
Claim 13
Dependent Claim
14 words
The modified-live virus vaccine as claimed in claim 8, wherein said mutagen is 5-bromodeoxyuridine.
Claim 14
Dependent Claim
22 words
The modified-live virus vaccine as claimed in claim 8, wherein said pharmaceutical effective amount is about 10 6 to 10 8 PFU.
Claim 15
Independent Claim
126 words
A method of immunizing an animal against infectious bovine rhinotracheitis comprising administering a pharmaceutically effective amount of a temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation, prepared by the process comprising: (1) propagating thymidine kinase-positive bovine herpesvirus-1 in thymidine kinase-positive cells at about 34.5° C. in the presence of a mutagen and selecting for thymidine kinase-negative bovine herpesvirus-1; (2) plaque-purifying the resulting thymidine kinase-negative bovine herpesvirus-1 so as obtain bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase; and (3) propagating the resulting plaque-purified thymidine kinase-negative bovine herpes-virus-1 mutants in thymidine kinase-positive cells at about 39.1° C. and selecting for temperature-resistant bovine herpes-virus-1 mutants which fail to produce any functional thymidine kinase to an animal.
Claim 16
Independent Claim
126 words
A method of immunizing an animal against infectious bovine rhinotracheitis comprising administering a pharmaceutically effective amount of a temperature-resistant bovine herpesvirus-1 which fails to produce any functional thymidine kinase as a result of mutagen-induced mutation, prepared by the process comprising: (1) propagating thymidine kinase-positive bovine herpesvirus-1 in thymidine kinase-positive cells at about 34.5° C. in the presence of a mutagen and selecting for thymidine kinase-negative bovine herpesvirus-1; (2) plaque-purifying the resulting thymidine kinase-negative bovine herpesvirus-1 so as obtain bovine herpesvirus-1 mutants which fail to produce any functional thymidine kinase; and (3) propagating the resulting plaque-purified thymidine kinase-negative bovine herpes-virus-1 mutants in thymidine kinase-positive cells at about 39.1° C. and selecting for temperature-resistant bovine herpes-virus-1 mutants which fail to produce any functional thymidine kinase to an animal.
Claim 17
Dependent Claim
18 words
The method as claimed in claim 11, wherein said virus has the identifying characteristics of ATCC No. VR-2066.
Claim 18
Dependent Claim
12 words
The method as claimed in claim 11, wherein said mutagen is 5-bromodeoxyuridine.
Claim 19
Dependent Claim
15 words
The method as claimed in claim 11, wherein said administering is conducted intranasally or parenterally.
Claim 20
Dependent Claim
21 words
The method as claimed in claim 11, wherein said animal is selected from the group consisting of bovine, goats and swine.
Claim 21
Dependent Claim
10 words
The method of claim 15, wherein said animal is bovine.
Claim 22
Dependent Claim
17 words
The method of claim 11, wherein said pharmaceutically effective amount is 10 6 to 10 8 PFU.
References Cited (Backward Citations)
US3876764A
Cited
US3907986A
Cited
US4132775A
Cited
US4291019A
Cited
US4282210A
Cited
US4322404A
Cited
US4514497A
Cited
US4514497B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-02-10 | 1989-08-12 | 1990-02-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-02-10 | 1993-08-12 | 1994-02-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-02-10 | 1997-08-12 | 1998-02-11 | $7700.00 | Window Closed / Lapsed |